Sickle Cell Disease Market Report

To learn more about this report, Download Free Sample Report

Global Sickle Cell Disease Market Size

The global sickle cell disease market size was valued at USD 4.02 billion in 2025 and is estimated to reach USD 23.02 billion by 2034 from USD 4.88 billion in 2026, registering a CAGR of 21.4% from 2026 to 2034.

Sickle Cell Infection (SCD) is an acquired problem causing illnesses like hemoglobin sickle cell sickness, hemoglobin SS sickness, and others causing the mishappening of red platelets. This prompts the early demise of cells, causing blood lack and furthermore hinders the bloodstream causing a blockage. Medication, blood transfusions, and bone marrow transplants are used to treat diseases. The World Health Organization and the United Nations recognize sickle cell disease as a global health issue, as reported by Sickle-Cell.com. Countries with high levels of poverty have not yet received many of the treatments for sickle cell disease that have been developed. The number of SCD cases worldwide is not accurately estimated. But every year, 300,000 infants are born with sickle cell anemia. Most of these occurrences take place in the Democratic Republic of the Congo, Nigeria, and India.  By 2050, experts estimate that this number will surpass 400,000. Because of improved SCD diagnosis and treatment, infant mortality is decreasing in low- and middle-income nations.

For example, 40% of individuals in a few African nations have sickle cell trait. In nations with poor assets, over 90% of youngsters with SCD don't get it by adulthood. The rising incidence of sickle cell disease (SCD), rising public awareness of the condition, and a growing focus on the development of new, efficient treatments by major players are all contributing factors to the expansion of the global sickle cell disease treatment market.

MARKET DRIVERS

The increasing prevalence of sickle cell disease and the increasing R&D activities regarding sickle cell disease are primarily driving the growth of the global market. Sickle cell disease affects millions of people throughout the world. The prevalence of SCD disease has been increasing at a faster pace. SCD is more common in Americans whose ancestors lived in Africa, South and Central America, and India. For instance, in May 2022, as per the data published and updated by the CDC, the disease affected nearly 100,000 Americans. The U.S. Centers for Disease Control and Prevention (CDC) projects that about 1 in every 13 Blacks have sickle cell trait.

The expected launch of new drugs to treat sickle cell disease is further fuelling the growth rate of the global market. The Vaso-occlusive Crisis (VOC) is a common painful complication of sickle cell disease in adolescents and adults. It causes acute episodes of severe pain. Patients, including adults and children, need to seek emergency medical care. As per a research study published by NCBI in 2021, patients who have the disease can experience up to 18 VOCs in a year. Major companies operating in the market have increased their focus on the launch of drugs to reduce the severity of these diseases and treat painful complications associated with them. For instance, Adakveo, approved by the FDA in November 2019, generated a revenue of USD 164.0 million in 2021, experiencing a growth of USD 56.2% from the prior year.

The emergence of new treatment modalities is boosting the growth of the sickle cell disease market. The emergence of new treatment modalities is another growth driver of the SCD market. Earlier, SCD management only involved blood transfusion and bone marrow transplantation. The rising awareness regarding the disease increased the demand for other effective treatment types. Moreover, the FDA and EMA also play a significant role by providing speedy approval for these products. FDA provides accelerated approval to drugs for serious conditions to fill an unmet medical need based on a result that is reasonably likely to predict a clinical benefit to patients. In November 2019, Global Blood Therapeutics (Pfizer Inc.) announced the FDA approval of Oxbryta 3 months before a statutory deadline for agency action. The expected launch of new drugs in the forecast period and the rising prevalence of the disease are likely to fuel the market growth.

MARKET RESTRAINTS

Limited Availability of Treatment Options for SCD in developing countries is hampering the global market. Hydroxyurea and a few marketed medications make up sickle cell disease pharmacotherapy. Many medical specialists advise using hydroxyurea as the first line of treatment for illnesses. But one barrier that sticks out as a deterrent is the absence of treatment choices in many nations, particularly in low-resource settings and areas with weak healthcare infrastructure. Around 300,000 infants are born with SCD each year in Sub-Saharan Africa, according to the American Society of Haematology. Despite being listed on the WHO Model List of Essential Medicines for Children, hydroxyurea is still not available in the area. The medication is also seen as being overly pricey in Africa. Additionally, blood transfusions for SCD treatment rely on the availability of donors. Even if the donors are accessible, there is a potential for insufficient screening, which might increase infections contracted through blood transfusions. Furthermore, when combined with the population's lack of knowledge about the conditions in emerging nations, it may restrain the expansion of the global market throughout the forecast period.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Treatment Modality Insights

The segment with the most significant revenue is blood transfusions, which are anticipated to increase at a CAGR that will remain constant throughout the course of the projection period. Strokes are one of the severe symptoms of SCD, and blood transfusion is the most effective management strategy. The demand for blood transfusion therapy has grown because of the rise in stroke occurrences among SCD patients. The segment's dominance is caused by this element. Additionally, the pharmacotherapy segment is anticipated to grow at the fastest CAGR during the forecast period. The introduction of new branded pharmaceutical medications and growing government emphasis on early releases of these drugs are to blame for the segment's rapid growth rate. These elements are anticipated to hasten the entry of new, branded pharmacotherapy medications into the market and provide the pharmacotherapy sector with a major boost.

By End-user Insights

Based on end-users, the hospital's segment accounted for a significant global sickle cell disease treatment market share. The significant market share is related to the increased incidence of SCD illness and the rise in hospital admissions for the treatment of sickle cell anemia. The WHO estimates that 20–25 million individuals worldwide are afflicted with the illness. Additionally, a 30% rise in patients is anticipated by 2050, which would help the hospital segment flourish.

During the forecast period, the specialty clinics segment is anticipated to expand at a considerable CAGR. The rise in the number of specialized clinics offering care and sickle cell disease treatment is responsible for this market segment's expansion.

REGIONAL ANALYSIS

By region, the North American market has the highest proportion of the global market. Better access to SCD therapy, promising pipeline prospects, strong government backing, and growing partnerships to advance the disease's treatment are all credited with the domination of the market in the nation. Most Americans with SCD survive until adulthood—more than 90%.

The market in Europe held a sizeable portion of the overall industry and is anticipated to expand significantly over the next years. The advantageous reimbursement policies, rising illness prevalence, and growing market participants' focus on extending their product offerings in the area are all considered contributing factors to the market growth in Europe. Approximately 1 in 10,000 persons in the European Economic Area (EEA) had the disorder in 2019, according to statistics from the European Medicines Agency (EMA).

In the coming years, the rest of the world is expected to grow at a considerable CAGR. The strong market growth in the area is linked to rising disposable incomes and the greatest prevalence of SCD in Africa, the Middle East, South America, and the Mediterranean areas. Additionally, the region's market is anticipated to develop as a result of rising SCD awareness and a robust pipeline of branded medications.

KEY MARKET PLAYERS

Some of the notable key market players are Bristol-Myers Squibb Company (U.S.), Addmedica (France), Novartis AG (Switzerland), Global, Blood Therapeutics, Inc. (Pfizer Inc.) (U.S.), Emmaus Medical, Inc. (U.S.), bluebird bio-Inc. (U.S.) and Agios Pharmaceuticals, Inc. (U.S.).

RECENT MARKET DEVELOPMENTS

• In August 2022, the U.S. commercial infrastructure for supporting quick access to ZYNTEGLO has been described in full by Bluebird Bio Inc. It consists of an innovative, outcomes-based contract offering and a complete patient care program.
• In November 2021, to increase patient access to Endari, Emmaus Life Sciences, Inc. and UpScript IP Holdings, LLC (UpScript) have partnered to offer telehealth options to patients.
• In September 2020, Global Blood Therapeutics, Inc. inked an exclusive agreement with Biopharma-MEA to distribute Oxbryta in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.

MARKET SEGMENTATION

The sickle cell disease market has been segmented & sub-segmented based on treatment modality analysis, end-user and region.

By Treatment Modality

• Bone Marrow Transplant
• Blood Transfusion
• Pharmacotherapy
  • Hydroxyurea
  • Branded Products

By End-user

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East & Africa